Moreover, a most recent report from Gagliato et al [9] indicates that the delayed adjuvant chemotherapy is particularly meaningful for patients with advanced disease, triple-negative breast cancer (TNBC), and trastuzumab-treated HER2-positive (HER2+) tumors. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.